Unravelling Immune Enhancement by Immulina

揭秘 Immulina 的免疫增强作用

• 批准号: 9916572
• 负责人: Chalet Tan
• 金额: $ 32.46万
• 依托单位: UNIVERSITY OF MISSISSIPPI
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9916572
• 关键词: Acute; Agonist; Antigens; Binding; Biological; Biological Assay; Biological Markers; Blood Circulation; CD8-Positive T-Lymphocytes; Cells; Data; Dendritic Cells; Development; Disease; Dose; Drug Delivery Systems; Effector Cell; Extracellular Space; Food; Formulation; Gel; Generations; Health; Homeostasis; Host Defense; Human; Immune; Immune response; Immunity; Immunologics; Immunology; In Vitro; Influenza; Interleukin 2 Receptor Gamma; Interleukin-15; Interleukin-2; Knowledge; Lipoproteins; Liquid substance; Lung; Lymphoid; Mediating; Mississippi; Molecular; Morbidity - disease rate; Mus; Natural Immunity; Natural Killer Cells; Natural Products; Peyer' s Patches; Pharmacodynamics; Pharmacology; Phase; Play; Population; Process; Production; Proteins; Respiratory System; Role; Scientist; Signal Transduction; Site; Small Intestines; Spirulina preparation; Standardization; T memory cell; TLR2 gene; Toll-like receptors; Universities; Virus; Virus Diseases; Virus Replication; Weight; Work; Zoonoses; adaptive immune response; adaptive immunity; capsule; cytokine; draining lymph node; experience; improved; in vivo; influenzavirus; intestinal epithelium; liquid formulation; macrophage; migration; monocyte; mortality; mouse toll-like receptor 2; oral supplementation; pandemic disease; protective effect; receptor; resilience; respiratory infection virus

PROJECT SUMMARY Influenza is an acute respiratory virus infection that poses endemic, zoonotic and pandemic threats to human health with significant morbidity and mortality. Natural killer (NK) cells and virus-specific CD8 T cells are key effector cells in launching effective immune responses against influenza virus infection. ImmulinaTM, a high molecule-weight fraction of Spirulina extract, contains Braun-type lipoproteins that trigger Toll-like receptor 2 (TLR2)-mediated NFκB activation in human monocytes and mouse macrophages. Our recent preliminary data show that daily treatment of a liquid formulation of Immulina caused notable expansion of circulating NK population in mice. Building upon our substantial experience in drug delivery, pharmacodynamics and immunology, we propose to develop an optimized liquid formulation of Immulina, evaluate its protective effect against influenza virus infection, and elucidate the mechanism of action in vitro and in vivo. The specific aims of the proposal are: (1) develop an optimized liquid formulation for Immulina; (2) evaluate the pharmacodynamics of Immulina and identify in vivo biomarker(s); (3) investigate the molecular mechanism on the immune enhancement by Immulina. The successful completion of this project will result in the development of an improved formulation of Immulina and the identification of in vivo biomarkers for Immulina treatment.

项目摘要 流感是一种急性呼吸道病毒感染，构成内在，人畜共患病和大流行威胁 人类健康具有明显的发病率和死亡率。天然杀手（NK）细胞和病毒特异性CD8 T细胞是 关键效应细胞在发射针对影响力病毒感染的有效免疫反应中。 immulinatm，高 螺旋藻提取物的分子量分数，含有触发类似Toll样受体2的Braun型脂蛋白 （TLR2）在人单核细胞和小鼠巨噬细胞中介导的NFκB激活。我们最近的初步数据 表明每日治疗液态液体的疫苗公式引起了循环NK的显着膨胀 小鼠的人口。基于我们在药物输送，药效学和 免疫学，我们建议开发一种优化的侵害液式，评估其保护作用 反对影响力病毒感染，并阐明体外和体内作用机理。具体目标 该提案的内容是：（1）开发出一种优化的液体配方； （2）评估 侵犯的药物动力学并鉴定体内生物标志物（S）； （3）研究分子机制 免疫增强免疫。该项目的成功完成将导致开发 改进的疫苗公式和用于疫苗治疗的体内生物标志物的鉴定。